Skip to main content
Premium Trial:

Request an Annual Quote

Corrections:

Premium

In the 12/21/01 article “Could Microarrays Replace Sequencers? Callida Genomics Thinks So,” Rade Drmanac, the chief scientific officer of Callida, was erroneously referred to as the chief executive officer. Also, Hyseq owns more than the 50 percent share of Callida indicated in the article, and Affymetrix provided an undisclosed sum to the company, not exactly $1.5 million.

 

In the 2/22/02 issue, the Patent Watch stated that Arcturus’ RiboAmp RNA Amplification Kit sells for a list price of $1,125. This is out of date: Since November 2001, the kit has sold for a list price of $695.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.